TCBP חוב כולל להון TC BioPharm Ltd

Current price action for TC Biopharm (TCBP) reflects the company's financial standing as management currently aligns internal cycles for early therapy tests. The individual debt-to-equity ratio stands at 0.88. The business relies on the development of patented leukemia treatment methods while awaiting FDA data. The team brings together leading scientists attracted by the modern infrastructure and the opportunity to share profits from breakthroughs in oncology.

Investors utilize this ratio to assess financial stability and the extent of the business's reliance on external borrowings. The total liabilities-to-equity ratio, reflected through changes in the total debt-to-equity level, is critical for TC Biopharm (TCBP), as the costs of clinical trials for leukemia therapy require a balance between debt load and investment potential.